• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by GoodRx Holdings Inc. (Amendment)

    3/8/24 4:26:51 PM ET
    $GDRX
    EDP Services
    Technology
    Get the next $GDRX alert in real time by email
    SC 13D/A 1 d745199dsc13da.htm SC 13D/A SC 13D/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13D/A

    (Rule 13d-101)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO

    § 240.13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a)

    (Amendment No. 1)*

     

     

    GoodRx Holdings, Inc.

    (Name of Issuer)

    Class A Common Stock

    (Title of Class of Securities)

    38246G108

    (CUSIP Number)

    Steve Eisner

    Francisco Partners

    One Letterman Drive,

    Building C - Suite 410

    San Francisco, CA 94129

    (415) 418-2900

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    March 6, 2024

    (Date of Event which Requires Filing of this Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-l(e), 240.13d-l(f) or 240.13d-l(g), check the following box. ☐

     

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240 13d-7 for other parties to whom copies are to be sent.

     

     

     

    1 

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes’).

     

     

     


     1.    

     Names of Reporting Persons

     

     Francisco Partners IV, L.P.

     2.  

     Check The Appropriate Box if a Member of a Group (See Instructions)

     (a) ☒  (b) ☐

     

     3.  

     SEC Use Only

     

     4.  

     Source of Funds

     

     OO

     5.  

     Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

     

     6.  

     Citizenship or Place of Organization

     

     Cayman Islands

    Number of

    Shares

     Beneficially 

    Owned By

    Each

    Reporting

    Person

    With

     

        7.    

     Sole Voting Power

     

     0

        8.  

     Shared Voting Power

     

     46,680,496

        9.  

     Sole Dispositive Power

     

     0

       10.  

     Shared Dispositive Power

     

     46,680,496

    11.    

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     46,680,496

    12.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

     ☐

    13.  

     Percent of Class Represented by Amount in Row (9)

     

     28.6%(1)

    14.  

     Type of Reporting Person (See Instructions)

     

     PN

     

    (1)

    Calculated assuming 163,343,928 shares of Class A Common Stock (“Class A Shares”) outstanding, based upon 93,265,744 Class A Shares outstanding as of February 20, 2024 as reported on the Issuer’s Form 10-K filed on February 29, 2024 (the “10-K”), as increased by 70,078,184 shares of Class B Common Stock, which are convertible into Class A Shares on a one-to-one basis (“Class B Shares”), held by the Reporting Persons following the March 2024 Francisco Partners Repurchase, as defined below.


     1.    

     Names of Reporting Persons

     

     Francisco Partners IV-A, L.P.

     2.  

     Check The Appropriate Box if a Member of a Group (See Instructions)

     (a) ☒  (b) ☐

     

     3.  

     SEC Use Only

     

     4.  

     Source of Funds

     

     OO

     5.  

     Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

     

     6.  

     Citizenship or Place of Organization

     

     Cayman Islands

    Number of

    Shares

     Beneficially 

    Owned By

    Each

    Reporting

    Person

    With

     

        7.    

     Sole Voting Power

     

     0

        8.  

     Shared Voting Power

     

     23,397,688

        9.  

     Sole Dispositive Power

     

     0

       10.  

     Shared Dispositive Power

     

     23,397,688

    11.    

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     23,397,688

    12.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

     ☐

    13.  

     Percent of Class Represented by Amount in Row (9)

     

     14.3%(1)

    14.  

     Type of Reporting Person (See Instructions)

     

     PN

     

    (1)

    Calculated assuming 163,343,928 Class A Shares outstanding, based upon 93,265,744 Class A Shares outstanding as of February 20, 2024 as reported on the 10-K, as increased by 70,078,184 Class B Shares held by the Reporting Persons following the March 2024 Francisco Partners Repurchase, as defined below.


     1.    

     Names of Reporting Persons

     

     Francisco Partners GP IV, L.P.

     2.  

     Check The Appropriate Box if a Member of a Group (See Instructions)

     (a) ☒  (b) ☐

     

     3.  

     SEC Use Only

     

     4.  

     Source of Funds

     

     OO

     5.  

     Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

     

     6.  

     Citizenship or Place of Organization

     

     Cayman Islands

    Number of

    Shares

     Beneficially 

    Owned By

    Each

    Reporting

    Person

    With

     

        7.    

     Sole Voting Power

     

     0

        8.  

     Shared Voting Power

     

     70,078,184

        9.  

     Sole Dispositive Power

     

     0

       10.  

     Shared Dispositive Power

     

     70,078,184

    11.    

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     70,078,184

    12.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

     ☐

    13.  

     Percent of Class Represented by Amount in Row (9)

     

     42.9%(1)

    14.  

     Type of Reporting Person (See Instructions)

     

     PN

     

    (1)

    Calculated assuming 163,343,928 Class A Shares outstanding, based upon 93,265,744 Class A Shares outstanding as of February 20, 2024 as reported on the 10-K, as increased by 70,078,184 Class B Shares held by the Reporting Persons following the March 2024 Francisco Partners Repurchase, as defined below.


     1.    

     Names of Reporting Persons

     

     Francisco Partners GP IV Management Limited

     2.  

     Check The Appropriate Box if a Member of a Group (See Instructions)

     (a) ☒  (b) ☐

     

     3.  

     SEC Use Only

     

     4.  

     Source of Funds

     

     OO

     5.  

     Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

     

     6.  

     Citizenship or Place of Organization

     

     Cayman Islands

    Number of

    Shares

     Beneficially 

    Owned By

    Each

    Reporting

    Person

    With

     

        7.    

     Sole Voting Power

     

     0

        8.  

     Shared Voting Power

     

     70,078,184

        9.  

     Sole Dispositive Power

     

     0

       10.  

     Shared Dispositive Power

     

     70,078,184

    11.    

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     70,078,184

    12.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

     ☐

    13.  

     Percent of Class Represented by Amount in Row (9)

     

     42.9%(1)

    14.  

     Type of Reporting Person (See Instructions)

     

     CO

     

    (1)

    Calculated assuming 163,343,928 Class A Shares outstanding, based upon 93,265,744 Class A Shares outstanding as of February 20, 2024 as reported on the 10-K, as increased by 70,078,184 Class B Shares held by the Reporting Persons following the March 2024 Francisco Partners Repurchase, as defined below.


     1.    

     Names of Reporting Persons

     

     Francisco Partners Management, L.P.

     2.  

     Check The Appropriate Box if a Member of a Group (See Instructions)

     (a) ☒  (b) ☐

     

     3.  

     SEC Use Only

     

     4.  

     Source of Funds

     

     OO

     5.  

     Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

     

     6.  

     Citizenship or Place of Organization

     

     Delaware

    Number of

    Shares

     Beneficially 

    Owned By

    Each

    Reporting

    Person

    With

     

        7.    

     Sole Voting Power

     

     0

        8.  

     Shared Voting Power

     

     70,078,184

        9.  

     Sole Dispositive Power

     

     0

       10.  

     Shared Dispositive Power

     

     70,078,184

    11.    

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     70,078,184

    12.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

     ☐

    13.  

     Percent of Class Represented by Amount in Row (9)

     

     42.9%(1)

    14.  

     Type of Reporting Person (See Instructions)

     

     PN

     

    (1)

    Calculated assuming 163,343,928 Class A Shares outstanding, based upon 93,265,744 Class A Shares outstanding as of February 20, 2024 as reported on the 10-K, as increased by 70,078,184 Class B Shares held by the Reporting Persons following the March 2024 Francisco Partners Repurchase, as defined below.


    Item 1.

    Security and Issuer

    The information set forth in response to each separate Item below shall be deemed to be a response to all Items where such information is relevant.

    This Amendment No. 1 (“Amendment No. 1”) is being filed by the undersigned to amend the Schedule 13D filed with the SEC on June 1, 2021 (the “Original 13D” and, as amended by Amendment No. 1, the “Schedule 13D”) relating to shares of common stock (the “Common Stock”), of GoodRx Holdings, Inc., a Delaware corporation (the “Issuer”), whose principal executive office is located at 2701 Olympic Boulevard, Santa Monica, California 90404. Except as set forth herein, the Original 13D is unmodified and remains in full force and effect. Capitalized terms used herein and not otherwise defined in this Amendment No. 1 have the meanings set forth in the Original 13D.

     

    Item 2.

    Identity and Background.

    The Schedule 13D is being filed by the following entities (each a “Reporting Person” and collectively, the “Reporting Persons”):

    Francisco Partners IV, L.P.

    Francisco Partners IV-A, L.P.

    Francisco Partners GP IV, L.P.

    Francisco Partners GP IV Management Limited

    Francisco Partners Management, L.P.

    Francisco Partners Management, L.P. is organized under the laws of the state of Delaware. The remaining Reporting Persons are organized under the laws of the Cayman Islands. The principal business address of the Reporting Persons is One Letterman Drive, Building C, Suite 410, San Francisco, CA 94129. The Reporting Persons are principally engaged in the business of managing their investments in the securities of the Issuer.

    Information with respect to the directors and officers of Francisco Partners GP IV Management Limited (collectively, the “Related Persons”), including the name, business address, present principal occupation or employment and citizenship of each of the Related Persons is listed on the attached Schedule A, which is incorporated herein by reference.

    By virtue of the agreements made pursuant to the Stockholders Agreement (as defined below), the Reporting Persons, Idea Men, LLC and certain affiliates of Spectrum Equity and Silver Lake (collectively, the “Stockholders”) acknowledge and agree that they are acting as a group for purposes of Rule 13d-3 under the Securities and Exchange Act of 1934, as amended (the “Exchange Act”). Shares beneficially owned by the other Stockholders are not the subject of this Schedule 13D. For a description of the relationship between the Reporting Persons and the other Stockholders, see Item 4 below.

    During the last five years, neither the Reporting Persons nor any Related Persons (i) has been convicted in any criminal proceeding (excluding traffic violations or similar misdemeanors) or (ii) was a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

     

    Item 4.

    Purpose of Transaction.

    Item 4 of the Original 13D is hereby amended to include the following at the end thereof:

    On March 6, 2024, Francisco Partners IV, L.P. and Francisco Partners IV-A, L.P. (collectively, the “Selling Stockholders”) and the Issuer entered into a Stock Purchase Agreement (the “March 2024 Francisco Partners Stock Purchase Agreement”), pursuant to which the Selling Stockholders agreed to sell an aggregate 14,622,366 Class A Shares to the Issuer for net proceeds of $105,134,811.54 (the “March 2024 Francisco Partners Repurchase”). The March 2024 Francisco Partners Repurchase is expected to close on March 11, 2024.


    Item 5.

    Interest in the Securities of the Issuer

    Items 5(a), (b) and (c) of the Schedule 13D are hereby amended and restated as follows:

    (a) and (b)

    The following sets forth, as of the date of this Schedule 13D, the aggregate number of Class A Shares and percentage of Class A Shares beneficially owned by each of the Reporting Persons (assuming conversion of the Class B Shares held by the Reporting Persons), assuming 163,343,928 Class A Shares outstanding, based upon 93,265,744 Class A Shares outstanding as of February 20, 2024 as reported on the 10-K, as increased by 70,078,184 Class B Shares held by the Reporting Persons following the March 2024 Francisco Partners Repurchase.

     

    Reporting Person

       Amount
    beneficially
    owned
         Percent
    of class
        Sole power
    to vote or
    to direct
    the vote
         Shared
    power to
    vote or to
    direct the
    vote
         Sole power
    to dispose
    or to direct
    the
    disposition
         Shared
    power to
    dispose or to
    direct the
    disposition
     

    Francisco Partners IV, L.P.

         46,680,496        28.6 %      0        46,680,496        0        46,680,496  

    Francisco Partners IV-A, L.P.

         23,397,688        14.3 %      0        23,397,688        0        23,397,688  

    Francisco Partners GP IV, L.P.

         70,078,184        42.9 %      0        70,078,184        0        70,078,184  

    Francisco Partners GP IV Management Limited

         70,078,184        42.9 %      0        70,078,184        0        70,078,184  

    Francisco Partners Management, L.P.

         70,078,184        42.9 %      0        70,078,184        0        70,078,184  

    Francisco Partners IV, L.P. is the record holder of 46,680,496 Class B Shares. Francisco Partners IV-A, L.P. is the record holder of 23,397,688 Class B Shares. The Class B Shares are convertible to Class A Shares on a one-to-one basis.

    Francisco Partners GP IV, L.P. is the general partner of each of Francisco Partners IV, L.P. and Francisco Partners IV-A, L.P. Francisco Partners GP IV Management Limited is the general partner of Francisco Partners GP IV, L.P. Francisco Partners Management, L.P. serves as the investment manager for each of Francisco Partners IV, L.P. and Francisco Partners IV-A, L.P. Voting and disposition decisions at Francisco Partners Management, L.P. with respect to the shares of Class B Common Stock held by Francisco Partners IV, L.P. and Francisco Partners IV-A, L.P. are made by an investment committee. Each of Francisco Partners Management, L.P., Francisco Partners GP IV Management Limited, and Francisco Partners GP IV, L.P. may be deemed to share voting and dispositive power over the Class B Shares held, but disclaims beneficial ownership.

    In addition, as discussed in Item 2 above, by virtue of the agreements made pursuant to the Stockholders Agreement, the Stockholders acknowledge and agree that they are acting as a group for purposes of Rule 13d-3 under the Exchange Act. Shares beneficially owned by the other Stockholders are not the subject of this Schedule 13D and accordingly, none of the other Stockholders are included as reporting persons herein.

    (c) During the past 60 days, the Reporting Persons have not effected any transactions with respect to the Class A Shares.

     

    Item 6.

    Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

    March 2024 Stock Purchase Agreement

    On March 6, 2024, the Selling Stockholders and the Issuer entered into the March 2024 Francisco Partners Stock Purchase Agreement, pursuant to which the Issuer will purchase from the Selling Stockholders an aggregate 14,622,366 Class A Shares for an aggregate purchase price of $105,134,811.54. The March 2024 Francisco Partners Repurchase is expected to close on March 11, 2024.

    Pursuant to the March 2024 Francisco Partners Stock Purchase Agreement, the Selling Stockholders and their affiliates have entered into a Lock-Up, under which they will not, without the Issuer’s prior approval, sell, transfer, otherwise dispose of or enter into a hedging transaction involving any Class A Shares or Class B Shares until the completion of the second full trading day after the public release of earnings data for the quarter ended March 31, 2024, subject to certain limited exceptions.

     

    Item 7.

    Materials to be Filed as Exhibits

     

    Exhibit
    Number
      

    Description

    1    Joint Filing Agreement, incorporated by reference to Exhibit 1 to the Original 13D.


    SIGNATURE

    After reasonable inquiry and to the best of the undersigned’s knowledge and belief, each of the undersigned certifies that the information set forth in this Statement is true, complete and correct.

    Dated: March 8, 2024

     

    Francisco Partners IV, L.P.
    By: Francisco Partners GP IV, L.P., its general partner
    By: Francisco Partners GP IV Management Limited, its general partner
    By:  

    /s/ Steve Eisner

    Name:   Steve Eisner
    Title:   General Counsel and Chief Compliance Officer
    Francisco Partners IV-A, L.P.
    By: Francisco Partners GP IV, L.P., its general partner
    By: Francisco Partners GP IV Management Limited, its general partner
    By:  

    /s/ Steve Eisner

    Name:   Steve Eisner
    Title:   General Counsel and Chief Compliance Officer
    Francisco Partners GP IV, L.P.
    By: Francisco Partners GP IV Management Limited, its general partner
    By:  

    /s/ Steve Eisner

    Name:   Steve Eisner
    Title:   General Counsel and Chief Compliance Officer
    Francisco Partners GP IV Management Limited
    By:  

    /s/ Steve Eisner

    Name:   Steve Eisner
    Title:   General Counsel and Chief Compliance Officer
    Francisco Partners Management, L.P.
    By:  

    /s/ Steve Eisner

    Name:   Steve Eisner
    Title:   General Counsel and Chief Compliance Officer
    Get the next $GDRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GDRX

    DatePrice TargetRatingAnalyst
    1/22/2026$2.75Buy → Hold
    Jefferies
    12/9/2025$3.00Underweight
    Barclays
    8/11/2025Strong Buy → Outperform
    Raymond James
    12/4/2024$5.00Neutral
    Mizuho
    8/9/2024$10.00Outperform → Strong Buy
    Raymond James
    5/23/2024$8.00 → $10.00Sector Perform → Outperform
    RBC Capital Mkts
    5/16/2024$10.00Mkt Perform → Outperform
    Raymond James
    4/10/2024$9.00Sector Weight → Overweight
    KeyBanc Capital Markets
    More analyst ratings

    $GDRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    GoodRx Powers Pricing for Leading Brand Medications on TrumpRx

    Brief Summary: GoodRx is a core integration partner for TrumpRx, powering the pricing for leading brand medications At launch, GoodRx is the integrated pricing source on TrumpRx for Pfizer, including over 30 of Pfizer's essential brand medications spanning women's health, arthritis, and more By unifying pricing, pharmacy enablement, and a trusted consumer experience, GoodRx enables pharma manufacturers to rapidly deploy and scale emerging pricing models with minimal operational lift GoodRx (NASDAQ:GDRX), the leading platform for prescription savings in the U.S., today announced that it is a key integration partner for pharmaceutical companies offering discounted cash prices on T

    2/5/26 7:44:00 PM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Earns HITRUST i1 Certification for the Second Consecutive Year, Reinforcing Its Commitment to Protecting Healthcare Data at Scale

    Independent assessment validates GoodRx's continued leadership in cybersecurity and data protection GoodRx (NASDAQ:GDRX), the leading platform for prescription savings in the U.S., today announced it has earned its 2026 certification status for HITRUST i1 Certification for its prescription savings platform hosted on Amazon Web Services (AWS). This certification shows continuous dedication to GoodRx's prior HITRUST achievement and underscores the company's ongoing commitment to safeguarding sensitive healthcare information. The HITRUST i1 Certification demonstrates that GoodRx has met requirements defined by leading cybersecurity and regulatory frameworks, confirming that strong controls

    2/2/26 9:00:00 AM ET
    $GDRX
    EDP Services
    Technology

    60 Degrees Pharmaceuticals Expands Access to ARAKODA® with GoodRx Partnership

    GoodRx to offer prescription savings of up to 30% for ARAKODA® (tafenoquine)Collaboration designed to lower patient out-of-pocket costs and expand the reach of Company's marketing strategyPartnership will improve the affordability of ARAKODA at over 70,000 pharmacies nationwide for people planning travel to malaria-endemic regions WASHINGTON, Feb. 02, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW)) ("60 Degrees Pharma" or the "Company"), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced a partnership with GoodRx (NASDAQ:GDRX), the leading platform for prescription savings in the U.S., to offer eligible co

    2/2/26 8:01:00 AM ET
    $GDRX
    $SXTP
    EDP Services
    Technology
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GDRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    GoodRx downgraded by Jefferies with a new price target

    Jefferies downgraded GoodRx from Buy to Hold and set a new price target of $2.75

    1/22/26 8:25:34 AM ET
    $GDRX
    EDP Services
    Technology

    Barclays initiated coverage on GoodRx with a new price target

    Barclays initiated coverage of GoodRx with a rating of Underweight and set a new price target of $3.00

    12/9/25 8:49:54 AM ET
    $GDRX
    EDP Services
    Technology

    GoodRx downgraded by Raymond James

    Raymond James downgraded GoodRx from Strong Buy to Outperform

    8/11/25 9:45:40 AM ET
    $GDRX
    EDP Services
    Technology

    $GDRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Accounting Officer Nabiey Romin converted options into 12,663 shares and covered exercise/tax liability with 5,215 shares, increasing direct ownership by 5% to 172,923 units (SEC Form 4)

    4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

    2/9/26 5:49:36 PM ET
    $GDRX
    EDP Services
    Technology

    Director Wagner Scott converted options into 31,394 shares, increasing direct ownership by 17% to 216,663 units (SEC Form 4)

    4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

    1/21/26 5:20:35 PM ET
    $GDRX
    EDP Services
    Technology

    Officer Barnes Wendy Lynn converted options into 665,302 shares and covered exercise/tax liability with 237,309 shares (SEC Form 4)

    4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

    1/15/26 5:19:15 PM ET
    $GDRX
    EDP Services
    Technology

    $GDRX
    SEC Filings

    View All

    GoodRx Holdings Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - GoodRx Holdings, Inc. (0001809519) (Filer)

    12/12/25 4:26:49 PM ET
    $GDRX
    EDP Services
    Technology

    SEC Form 10-Q filed by GoodRx Holdings Inc.

    10-Q - GoodRx Holdings, Inc. (0001809519) (Filer)

    11/4/25 4:31:17 PM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - GoodRx Holdings, Inc. (0001809519) (Filer)

    11/4/25 4:23:32 PM ET
    $GDRX
    EDP Services
    Technology

    $GDRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Wagner Scott bought $124,806 worth of shares (21,652 units at $5.76) (SEC Form 4)

    4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

    12/4/23 4:35:10 PM ET
    $GDRX
    EDP Services
    Technology

    Wagner Scott bought $180,423 worth of shares (30,505 units at $5.91) (SEC Form 4)

    4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

    11/30/23 4:41:35 PM ET
    $GDRX
    EDP Services
    Technology

    Wagner Scott bought $677,475 worth of shares (130,743 units at $5.18) (SEC Form 4)

    4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

    11/17/23 7:08:30 PM ET
    $GDRX
    EDP Services
    Technology

    $GDRX
    Financials

    Live finance-specific insights

    View All

    GoodRx Announces Date for Fourth Quarter and Full Year 2025 Earnings Release and Conference Call

    GoodRx Holdings, Inc. (NASDAQ:GDRX) ("GoodRx" or the "Company"), the leading platform for prescription savings in the U.S., today announced it will release its fourth quarter and full year 2025 financial results after U.S. markets close on Wednesday, February 25, 2026. GoodRx management will also hold a conference call and webcast the following morning, Thursday, February 26, 2026 at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company's business outlook. To access the conference call, please pre-register using this link. Registrants will receive a confirmation with dial-in details and a unique passcode required to join. The call will also be webcast live

    1/28/26 4:05:00 PM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Reports Third Quarter 2025 Results

    Company Maintains Full Year 2025 Revenue and Adjusted EBITDA Expectations; Raises Pharma Manufacturer Solutions Revenue Outlook to Approximately 35% Year-Over-Year Growth for 2025 GoodRx Holdings, Inc. (NASDAQ:GDRX) ("we," "us," "our," "GoodRx," or the "Company"), the leading platform for medication savings in the U.S., has released its financial results for the third quarter of 2025. Third Quarter 2025 Highlights Revenue of $196.0 million Net income of $1.1 million; Net income margin of 0.6% Adjusted Net Income1 of $28.8 million; Adjusted Net Income Margin1 of 14.7% Adjusted EBITDA1 of $66.3 million; Adjusted EBITDA Margin1 of 33.8% Net cash provided by operating activities of

    11/4/25 4:05:00 PM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Announces Date for Third Quarter 2025 Earnings Release and Conference Call

    GoodRx Holdings, Inc. (NASDAQ:GDRX) ("GoodRx" or the "Company"), the leading platform for medication savings in the U.S., today announced it will release its third quarter 2025 financial results after U.S. markets close on Tuesday, November 4, 2025. GoodRx management will also hold a conference call and webcast the following morning, Wednesday, November 5, 2025 at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company's business outlook. To participate via telephone, please call (800) 715-9871 at least 10 minutes before the conference call is scheduled to begin. The conference ID is 9085550. The call will also be webcast live on the Company's investor relat

    10/8/25 4:05:00 PM ET
    $GDRX
    EDP Services
    Technology

    $GDRX
    Leadership Updates

    Live Leadership Updates

    View All

    GoodRx Appoints Amazon Pharmacy Veteran Laura Jensen as President of Pharma Solutions

    Seasoned industry leader tapped to help pharma reimagine their go-to-market strategies and direct-to-patient models GoodRx (NASDAQ:GDRX), the leading platform for medication savings in the U.S., today announced the appointment of Laura Jensen as Chief Commercial Officer and President of Pharma Solutions, effective July 28, 2025. In this role, Laura will lead the company's Pharma Manufacturer Solutions offering and oversee strategic initiatives aimed at growing and enhancing innovative partnerships across the pharmaceutical industry. Her deep cross-sector experience uniquely positions her to help revolutionize how patients access and afford their medications through the GoodRx platform. T

    7/28/25 9:00:00 AM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Open Sources Lifecycle to Support Innovation in Software Development Velocity and Developer Productivity

    Public release of Lifecycle reflects company's commitment to transparency, innovation, and community collaboration GoodRx (NASDAQ:GDRX), the leading platform for medication savings in the U.S., today announced it is open-sourcing Lifecycle, a homegrown development tool designed to improve team velocity, streamline review workflows, and reduce infrastructure overhead. Lifecycle is now available to the public under the Apache 2.0 license, inviting developers and organizations to adopt, contribute to, and build upon the platform. The tool allows engineering, quality assurance, and platform teams to automatically spin up short-lived, isolated environments—known as ephemeral environments—for

    6/5/25 9:00:00 AM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Appoints Aaron Crittenden as President of Rx Marketplace and Scott Pope, PharmD, as Chief Pharmacy Officer and Head of Clinical Engagement

    Accomplished healthcare executives will work to drive growth, strengthen industry partnerships, and enhance pharmacy innovation at GoodRx GoodRx (NASDAQ:GDRX), the leading platform for medication savings in the U.S., today announced the appointment of Aaron Crittenden as President of Rx Marketplace and Scott Pope, PharmD, as Chief Pharmacy Officer and Head of Clinical Engagement, effective immediately. Aaron will be responsible for the management and financial performance of GoodRx's Rx Marketplace offering, working with key retail pharmacy, pharmacy benefit manager (PBM), employer, and manufacturer partners. He will also play a critical role in shaping GoodRx's long-term growth strategy

    3/17/25 9:00:00 AM ET
    $GDRX
    EDP Services
    Technology

    $GDRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by GoodRx Holdings Inc.

    SC 13G/A - GoodRx Holdings, Inc. (0001809519) (Subject)

    11/14/24 12:29:56 PM ET
    $GDRX
    EDP Services
    Technology

    Amendment: SEC Form SC 13G/A filed by GoodRx Holdings Inc.

    SC 13G/A - GoodRx Holdings, Inc. (0001809519) (Subject)

    11/13/24 4:30:24 PM ET
    $GDRX
    EDP Services
    Technology

    Amendment: SEC Form SC 13G/A filed by GoodRx Holdings Inc.

    SC 13G/A - GoodRx Holdings, Inc. (0001809519) (Subject)

    11/12/24 4:02:41 PM ET
    $GDRX
    EDP Services
    Technology